Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Inclusion Criteria: * Must have newly diagnosed CD20+ large cell lymphoma. * Is ineligible for anthracycline-based therapy/cytotoxic chemotherapy due to: * Being age ≥80 years; AND/OR * Being age ≥75 years and having important comorbid condition(s), which are likely to have a negative impact on tolerability of anthracycline-based therapy/cytotoxic chemotherapy. * Have Immune Effector Cell-Associated Encephalopathy (ICE) score of at least 8 out of 10. * Have Ann Arbor Stage II-IV disease. * Have ECOG PS of 0, 1, or 2; (ECOG PS of 3 may be considered if impairment is attributed to current lymphoma/DLBCL and if pre-phase treatment during the screening phase results in an improvement of ECOG PS to ≤2 prior to enrollment). * Have measurable disease as per Lugano criteria. * Have acceptable organ function based on baseline bloodwork. * Must have fresh (preferred) or archival biopsy material at screening. Exclusion Criteria: * Has known active, clinically significant bacterial, viral, fungal, mycobacterial, parasitic, or other infection at trial enrollment, including COVID-19 infection. * Has severe cardiovascular disease (other than those eligibility criteria that preclude the subject from receiving anthracycline-based therapy/cytotoxic chemotherapy), * Has been exposed to/received any of the following prior therapies, treatments, or procedures within the specified timeframes: * Major surgery within 4 weeks prior to the first dose of epcoritamab; * Non-investigational …